Ginsenoside Rg1 attenuates neurogenesis disorder and neuronal apoptosis in the rat hippocampus after spinal cord injury may involve BDNF/ERK signaling

Zhiping Xie,Zhihua Wang,Shenke Xie,Zhiwu Wu,Wu Zhou,Chengcai Li,Meihua Li
DOI: https://doi.org/10.21203/rs.3.rs-1713893/v1
2022-01-01
Abstract:Abstract Our previous results have demonstrated that spinal cord injury(SCI) can induce hippocampus injury and depression in rodents. Ginsenoside Rg1 (Rg1) is one of the main active ingredients of Panax ginseng, which is efficient to prevent neurodegenerative disorders. However, no reports explain the effects of Rg1 in SCI-induced hippocampus injury. Neurotrophin brain-derived neurotrophic factor (BDNF)/extracellular signal-regulated kinase (ERK) signaling is important in neural differentiation, protection, and regeneration. However, the changes of BDNF/ERK signaling in the hippocampus after SCI is unclear. We used a rat compression SCI model to assess the changes of BDNF/ERK signaling in the hippocampus after SCI, and investigate the effects of Rg1(intraperitoneal injection) on the injured hippocampus. Western blotting and morphological assays demonstrated that BDNF/ERK signaling is altered in the hippocampus at 5 weeks after SCI. In addition, SCI attenuates neurogenesis and enhances the expression of cleaved caspase-3 in the hippocampus. Moreover, Rg1 could attenuate the expression of cleaved caspase-3, and improve neurogenesis and the expression of BDNF/p-ERK signaling in the rat hippocampus. The results thus suggested that SCI decreases the expression of BDNF/p-ERK signaling, and Rg1 could attenuate the changes of hippocampus after SCI. We speculate that the protective effects of Rg1 in hippocampus injury after SCI may involve BDNF/p-ERK signaling. Rg1 may serve as a therapeutic pharmaceutical product in the future when seeking to counter SCI-induced hippocampus injury.
What problem does this paper attempt to address?